Henry S A
Rev Infect Dis. 1985 Nov-Dec;7 Suppl 4:S729-33. doi: 10.1093/clinids/7.supplement_4.s729.
Response to aztreonam (1-2 g administered intravenously three or four times daily) was evaluated in a multiclinic study of 113 patients with intraabdominal infections due to gram-negative aerobic organisms. Appropriate therapy with an antibiotic (usually clindamycin) active against gram-positive and/or anaerobic organisms was administered concomitantly for mixed-pathogen infections. A favorable clinical response and microbiologic cure occurred in 90% of the patients treated. All of the 13 patients with infections due to Pseudomonas aeruginosa responded clinically, and 11 of the 13 patients experienced microbiologic cure. In a comparative study, 59 patients were treated with aztreonam and 56 were treated with tobramycin (3-5 mg/kg per day); 95% of the patients in the aztreonam group and 81% of those in the tobramycin group experienced microbiologic cure.
在一项针对113例由需氧革兰氏阴性菌引起的腹腔内感染患者的多中心研究中，评估了氨曲南（每日静脉注射1-2克，每日三或四次）的疗效。对于混合病原体感染，同时给予对革兰氏阳性和/或厌氧生物有效的抗生素（通常是克林霉素）进行适当治疗。接受治疗的患者中有90%出现了良好的临床反应和微生物学治愈。所有13例铜绿假单胞菌感染患者均有临床反应，13例患者中有11例实现了微生物学治愈。在一项对比研究中，59例患者接受氨曲南治疗，56例患者接受妥布霉素治疗（每日3-5毫克/千克）；氨曲南组95%的患者和妥布霉素组81%的患者实现了微生物学治愈。
